{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:44:20Z","timestamp":1791521060535,"version":"4.3.4"},"reference-count":34,"publisher":"American Society of Hematology","issue":"19","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapy (CART) for central nervous system lymphoma (CNSL) is a promising strategy, yet responses are frequently not durable. Bridging radiotherapy (BRT) is used for extracranial lymphoma in which it can improve CART outcomes through cytoreduction of high-risk lesions. We hypothesized that BRT would achieve similar, significant cytoreduction before CART for CNSL (CNS-BRT). We identified patients with CNSL with non-Hodgkin B-cell lymphoma who received CNS-BRT before commercial CART. Cytoreduction from CNS-BRT was calculated as change in lesion size before CART. Twelve patients received CNS-BRT, and the median follow-up among survivors is 11.8\u00a0months (interquartile range, 8.5-21.9). Ten patients had CNSL (9 secondary, 1 primary) and 2 patients had epidural disease (evaluable for toxicity). All 10 patients with CNSL had progressive disease at the time of CNS-BRT. Of 12 patients, 1 experienced grade \u22653 cytokine release syndrome, and 3 of 12 patients experienced grade \u22653 immune effector cell\u2013associated neurotoxicity syndrome. CNS-BRT achieved a 74.0% (95% confidence interval, 62.0-86.0) mean reduction in lesion size from baseline (P\u00a0=\u00a0.014) at a median of 12\u00a0days from BRT completion and before CART infusion. Best CNS response included 8 complete responses, 1 partial response, and 1 progressive disease. Three patients experienced CNS relapse outside the BRT field. Preliminary data suggest CNS-BRT achieves rapid cytoreduction and is associated with a favorable CNS response and safety profile. These data support further study of BRT as a bridging modality for CNSL CART.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013393","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T17:09:51Z","timestamp":1718125791000},"page":"5192-5199","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4749-6093","authenticated-orcid":false,"given":"Gustav Y.","family":"Cederquist","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javin","family":"Schefflein","sequence":"additional","affiliation":[{"name":"2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6801-720X","authenticated-orcid":false,"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[{"name":"3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"5Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8032","authenticated-orcid":false,"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"5Department of Medicine, Weill Cornell Medical College, New York, NY"},{"name":"6Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-5235","authenticated-orcid":false,"given":"Harper","family":"Hubbeling","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"7Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-4870","authenticated-orcid":false,"given":"Kathryn","family":"Tringale","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"8Department of Radiation Medicine and Applied Sciences, UC San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6290-1061","authenticated-orcid":false,"given":"Ana","family":"Alarcon Tomas","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"9Hematology and Hemotherapy Service, Hospital Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-7176","authenticated-orcid":false,"given":"Beatrice","family":"Fregonese","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8774-1845","authenticated-orcid":false,"given":"Carla","family":"Hajj","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7169-9275","authenticated-orcid":false,"given":"Alexander","family":"Boardman","sequence":"additional","affiliation":[{"name":"10Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2201-3091","authenticated-orcid":false,"given":"Alejandro","family":"Luna De Abia","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"11Adult Bone Marrow Transplantation Unit, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-0171","authenticated-orcid":false,"given":"Magdalena","family":"Corona","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2192-9930","authenticated-orcid":false,"given":"Giulio","family":"Cassanello","sequence":"additional","affiliation":[{"name":"10Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"12Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-3226","authenticated-orcid":false,"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"5Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-7880","authenticated-orcid":false,"given":"Richard J.","family":"Lin","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6986-7954","authenticated-orcid":false,"given":"Paola","family":"Ghione","sequence":"additional","affiliation":[{"name":"10Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"10Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"5Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-9156","authenticated-orcid":false,"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Weill Cornell Medical College, New York, NY"},{"name":"10Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1531-3838","authenticated-orcid":false,"given":"Lorenzo","family":"Falchi","sequence":"additional","affiliation":[{"name":"10Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9484-0240","authenticated-orcid":false,"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7485-0441","authenticated-orcid":false,"given":"Christian","family":"Grommes","sequence":"additional","affiliation":[{"name":"13Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1658-8585","authenticated-orcid":false,"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1281-5915","authenticated-orcid":false,"given":"Brandon S.","family":"Imber","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"14Department of Medicine, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"1","key":"2024100815203459800_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"2024100815203459800_bib2","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1182\/bloodadvances.2021005292","article-title":"CAR T-cell therapy for secondary CNS DLBCL","volume":"5","author":"Ahmed","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"2024100815203459800_bib3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2024100815203459800_bib4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2019-129097","article-title":"Experience with axicabtagene ciloleucel (Axi-cel) in patients with secondary CNS involvement: results from the US Lymphoma CAR T Consortium","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"issue":"20","key":"2024100815203459800_bib5","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2024100815203459800_bib6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024100815203459800_bib7","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41409-020-01099-4","article-title":"Axicabtagene ciloleucel CAR T-cell therapy for relapsed\/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?","volume":"56","author":"Ghafouri","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2024100815203459800_bib8","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3389\/fonc.2020.01306","article-title":"CAR T-cell therapy is effective but not long-lasting in B-cell lymphoma of the brain","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"2024100815203459800_bib9","doi-asserted-by":"crossref","first-page":"e3243","DOI":"10.1002\/hon.3243","article-title":"Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy","volume":"42","author":"Ababneh","year":"2024","journal-title":"Hematol Oncol"},{"issue":"5","key":"2024100815203459800_bib10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2024100815203459800_bib11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2024100815203459800_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024100815203459800_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radiother Oncol"},{"issue":"4","key":"2024100815203459800_bib14","doi-asserted-by":"crossref","first-page":"259.e1-e10","DOI":"10.1016\/j.jtct.2022.12.021","article-title":"Bridging radiation rapidly and effectively cytoreduces high-risk relapsed\/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy","volume":"29","author":"Hubbeling","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2024100815203459800_bib15","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdq548","article-title":"Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy","volume":"22","author":"Khimani","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"2024100815203459800_bib16","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ijrobp.2018.01.003","article-title":"Radiation therapy as an effective salvage strategy for secondary CNS lymphoma","volume":"100","author":"Milgrom","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2024100815203459800_bib17","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"issue":"4","key":"2024100815203459800_bib18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"key":"2024100815203459800_bib19","doi-asserted-by":"crossref","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"2024100815203459800_bib20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions","volume":"111","author":"Hunter","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"2024100815203459800_bib21","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"3","key":"2024100815203459800_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aag1266","article-title":"The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications","volume":"1","author":"Spiotto","year":"2016","journal-title":"Sci Immunol"},{"issue":"11","key":"2024100815203459800_bib23","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/0277-5379(91)90009-3","article-title":"Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma","volume":"27","author":"Ott","year":"1991","journal-title":"Eur J Cancer"},{"issue":"4","key":"2024100815203459800_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024100815203459800_bib25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"2024100815203459800_bib26","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1212\/WNL.0000000000200608","article-title":"Toxicities and response rates of secondary CNS lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T cells","volume":"98","author":"Karschnia","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"2024100815203459800_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","article-title":"Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study","volume":"16","author":"Epperla","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"10","key":"2024100815203459800_bib28","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A\u00a0real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"10254","key":"2024100815203459800_bib29","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"2024100815203459800_bib30","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024100815203459800_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"2024100815203459800_bib32","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"13","key":"2024100815203459800_bib33","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2024100815203459800_bib34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4\u00a0Gy versus 24\u00a0Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5192\/2245526\/blooda_adv-2024-013393-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/19\/5192\/2245526\/blooda_adv-2024-013393-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:10:28Z","timestamp":1728403828000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/19\/5192\/516464\/CNS-bridging-radiotherapy-achieves-rapid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":34,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013393","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]}}}